Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.58
ARAY's Cash-to-Debt is ranked lower than
74% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. ARAY: 0.58 )
Ranked among companies with meaningful Cash-to-Debt only.
ARAY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.92 Max: No Debt
Current: 0.58
Equity-to-Asset 0.12
ARAY's Equity-to-Asset is ranked lower than
93% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ARAY: 0.12 )
Ranked among companies with meaningful Equity-to-Asset only.
ARAY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.65  Med: 0.36 Max: 0.69
Current: 0.12
-0.65
0.69
Debt-to-Equity 3.25
ARAY's Debt-to-Equity is ranked lower than
98% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. ARAY: 3.25 )
Ranked among companies with meaningful Debt-to-Equity only.
ARAY' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.25  Med: 2.11 Max: 3.74
Current: 3.25
-0.25
3.74
Debt-to-EBITDA 17.26
ARAY's Debt-to-EBITDA is ranked lower than
98% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ARAY: 17.26 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ARAY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -112.23  Med: 6.68 Max: 80.83
Current: 17.26
-112.23
80.83
Interest Coverage N/A
ARAY's Interest Coverage is ranked higher than
71% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. ARAY: N/A )
Ranked among companies with meaningful Interest Coverage only.
ARAY' s Interest Coverage Range Over the Past 10 Years
Min: 88.63  Med: 88.63 Max: N/A
Current: N/A
Piotroski F-Score: 3
Altman Z-Score: 0.10
Beneish M-Score: -2.25
WACC vs ROIC
13.81%
-5.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1.37
ARAY's Operating Margin % is ranked lower than
58% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. ARAY: -1.37 )
Ranked among companies with meaningful Operating Margin % only.
ARAY' s Operating Margin % Range Over the Past 10 Years
Min: -25.53  Med: -3.74 Max: 1.28
Current: -1.37
-25.53
1.28
Net Margin % -7.49
ARAY's Net Margin % is ranked lower than
62% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ARAY: -7.49 )
Ranked among companies with meaningful Net Margin % only.
ARAY' s Net Margin % Range Over the Past 10 Years
Min: -32.67  Med: -8.66 Max: 2.56
Current: -7.49
-32.67
2.56
ROE % -60.32
ARAY's ROE % is ranked lower than
80% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. ARAY: -60.32 )
Ranked among companies with meaningful ROE % only.
ARAY' s ROE % Range Over the Past 10 Years
Min: -68.25  Med: -34.2 Max: 4.2
Current: -60.32
-68.25
4.2
ROA % -7.06
ARAY's ROA % is ranked lower than
58% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. ARAY: -7.06 )
Ranked among companies with meaningful ROA % only.
ARAY' s ROA % Range Over the Past 10 Years
Min: -21.75  Med: -7.03 Max: 1.72
Current: -7.06
-21.75
1.72
ROC (Joel Greenblatt) % -10.92
ARAY's ROC (Joel Greenblatt) % is ranked lower than
60% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. ARAY: -10.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARAY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -207.15  Med: -28.16 Max: 31.27
Current: -10.92
-207.15
31.27
3-Year Revenue Growth Rate -1.60
ARAY's 3-Year Revenue Growth Rate is ranked lower than
68% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ARAY: -1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARAY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.9  Med: 5.4 Max: 134.9
Current: -1.6
-6.9
134.9
3-Year EBITDA Growth Rate 36.80
ARAY's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ARAY: 36.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARAY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 21.85 Max: 54.5
Current: 36.8
0
54.5
3-Year EPS without NRI Growth Rate -8.50
ARAY's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ARAY: -8.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARAY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.8  Med: 2.2 Max: 91.3
Current: -8.5
-37.8
91.3
GuruFocus has detected 3 Warning Signs with Accuray Inc ARAY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARAY's 30-Y Financials

Financials (Next Earnings Date: 2018-01-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ARAY Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Jim Simons 4,207,500 sh (-1.85%)
Chuck Royce 1,572,177 sh (-2.88%)
PRIMECAP Management 5,513,300 sh (-26.43%)
Steven Cohen 122,800 sh (-47.54%)
» More
Q1 2017

ARAY Guru Trades in Q1 2017

Jim Simons 4,305,600 sh (+2.33%)
Steven Cohen Sold Out
PRIMECAP Management 5,512,800 sh (-0.01%)
Chuck Royce 1,571,077 sh (-0.07%)
» More
Q2 2017

ARAY Guru Trades in Q2 2017

Chuck Royce 1,676,077 sh (+6.68%)
Jim Simons 4,391,000 sh (+1.98%)
PRIMECAP Management 5,339,500 sh (-3.14%)
» More
Q3 2017

ARAY Guru Trades in Q3 2017

Paul Tudor Jones 10,353 sh (New)
Joel Greenblatt 12,282 sh (New)
Chuck Royce 1,682,577 sh (+0.39%)
PRIMECAP Management 5,332,500 sh (-0.13%)
Jim Simons 4,206,500 sh (-4.20%)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 New Buy$3.9 - $4.8 $ 4.8012%12,282
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:GNMK, XKRX:043150, NAS:VRAY, HKSE:01358, LSE:MGP, OHEL:DETEC, NYSE:IVC, HKSE:03600, XKRX:060280, XKRX:054950, OSTO:XVIVO, XKRX:099190, MIL:ELN, NAS:TCMD, XSWX:LIFE, NAS:RTIX, XKRX:228850, NAS:CUTR, TSE:7600, XTER:MF6 » details
Traded in other countries:XEJ.Germany,
Headquarter Location:USA
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Ratios

vs
industry
vs
history
PB Ratio 8.24
ARAY's PB Ratio is ranked lower than
81% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ARAY: 8.24 )
Ranked among companies with meaningful PB Ratio only.
ARAY' s PB Ratio Range Over the Past 10 Years
Min: 1.1  Med: 4.06 Max: 11.51
Current: 8.24
1.1
11.51
PS Ratio 1.04
ARAY's PS Ratio is ranked higher than
84% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. ARAY: 1.04 )
Ranked among companies with meaningful PS Ratio only.
ARAY' s PS Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.47 Max: 6.38
Current: 1.04
0.81
6.38
EV-to-EBIT -69.55
ARAY's EV-to-EBIT is ranked lower than
99.99% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. ARAY: -69.55 )
Ranked among companies with meaningful EV-to-EBIT only.
ARAY' s EV-to-EBIT Range Over the Past 10 Years
Min: -297.8  Med: -15.3 Max: 1222.2
Current: -69.55
-297.8
1222.2
EV-to-EBITDA 51.23
ARAY's EV-to-EBITDA is ranked lower than
88% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. ARAY: 51.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -666.8  Med: 29.8 Max: 802.8
Current: 51.23
-666.8
802.8
EV-to-Revenue 1.22
ARAY's EV-to-Revenue is ranked higher than
84% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. ARAY: 1.22 )
Ranked among companies with meaningful EV-to-Revenue only.
ARAY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 1.3 Max: 9.7
Current: 1.22
0.5
9.7
Current Ratio 1.48
ARAY's Current Ratio is ranked lower than
87% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. ARAY: 1.48 )
Ranked among companies with meaningful Current Ratio only.
ARAY' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.85 Max: 3.13
Current: 1.48
0.92
3.13
Quick Ratio 0.92
ARAY's Quick Ratio is ranked lower than
89% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ARAY: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
ARAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 1.44 Max: 2.67
Current: 0.92
0.65
2.67
Days Inventory 173.34
ARAY's Days Inventory is ranked lower than
63% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. ARAY: 173.34 )
Ranked among companies with meaningful Days Inventory only.
ARAY' s Days Inventory Range Over the Past 10 Years
Min: 70.63  Med: 136.44 Max: 199.92
Current: 173.34
70.63
199.92
Days Sales Outstanding 65.55
ARAY's Days Sales Outstanding is ranked higher than
51% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. ARAY: 65.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.56  Med: 63.29 Max: 101.57
Current: 65.55
49.56
101.57
Days Payable 33.80
ARAY's Days Payable is ranked lower than
83% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ARAY: 33.80 )
Ranked among companies with meaningful Days Payable only.
ARAY' s Days Payable Range Over the Past 10 Years
Min: 20.39  Med: 26.49 Max: 122.61
Current: 33.8
20.39
122.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
ARAY's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. ARAY: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.2  Med: -8.4 Max: -2.8
Current: -2.8
-66.2
-2.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.70
ARAY's Price-to-Median-PS-Value is ranked higher than
84% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. ARAY: 0.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARAY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.01 Max: 3.92
Current: 0.7
0.57
3.92
Earnings Yield (Greenblatt) % -1.44
ARAY's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. ARAY: -1.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARAY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.2  Med: -1.9 Max: 2.9
Current: -1.44
-26.2
2.9

More Statistics

Revenue (TTM) (Mil) $387.86
EPS (TTM) $ -0.34
Beta2.23
Short Percentage of Float6.89%
52-Week Range $3.60 - 6.00
Shares Outstanding (Mil)83.92

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}